Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v2-FR
Language English French
Date Updated 2022-03-15 2022-02-09
Drug Identification Number 02039508 02039508
Brand name GLYCOPYRROLATE INJECTION USP GLYCOPYRROLATE INJECTION USP
Common or Proper name GLYCOPYRROLATE GLYCOPYRROLATE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients GLYCOPYRROLATE GLYCOPYRROLATE
Strength(s) 0.2MG 0.2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML 10LIVI 2ML 10LIVI
ATC code A03AB A03AB
ATC description DRUGS FOR FUNCTIONAL BOWEL DISORDERS DRUGS FOR FUNCTIONAL BOWEL DISORDERS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2022-02-08 2022-02-08
Estimated end date 2022-03-18 2022-03-18
Actual end date 2022-03-14
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments